Search Results

Albumedix Ltd announces that Recombumin® is critical to the manufacture of the first FDA- licensed chikungunya vaccine.

Albumedix Ltd, Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc, Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed’s HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing.

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors.

Valneva’s inactivated COVID-19 vaccine, VLA2001, including Albumedix´ Recombinant Human Albumin (rHA) as an essential component, received regulatory approval from MHRA on April 14th.

Albumedix Ltd. (‘Albumedix’), an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company

Novartis and Albumedix Ltd. (‘Albumedix’) have entered into an agreement to evaluate the development of several first-in-class therapeutics using Albumedix’s Veltis® technology platform and associated technologies.

Albumedix has announced the formation of a Scientific Advisory Board (SAB) to provide governance, oversight and advice to Albumedix’s R&D organization as it builds and develops its pipeline of proprietary and differentiated drugs.